Trial Profile
A Phase 1, Randomized, Double Blind Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ID 93 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 14 Sep 2017 Status changed from active, no longer recruiting to completed.
- 26 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 18 Aug 2017.
- 14 Jul 2016 Status changed from recruiting to active, no longer recruiting.